- Email: [email protected]
Corrigendum to “Advances in medical treatment of hypertrophic cardiomyopathy” [J. Cardiol. 64 (2014) 1–10]
Journal of Cardiology 64 (2014) 330
Contents lists available at ScienceDirect
Journal of Cardiology journal homepage: www.elsevier.com/locate/jjcc
Corrigendum
Corrigendum to ‘‘Advances in medical treatment of hypertrophic cardiomyopathy’’ [J. Cardiol. 64 (2014) 1–10] Mareomi Hamada (MD, FJCC)a,*, Shuntaro Ikeda (MD)a, Yuji Shigematsu (MD, FJCC)b a b
Division of Cardiology, Uwajima City Hospital, 1-1 Goten-machi, Uwajima, Ehime 798-8510, Japan Clinical Nursing, Ehime University Graduate School of Medicine, Shitsukawa, Toon-City, Ehime 791-0295, Japan
The author regrets that some of the reference citations in the original publication of this article were incorrect. On Page 6, there is an incorrect citation of Ref. [59] within the caption of Fig. 5. Caption should read: ‘‘Fig. 5. Kaplan–Meier survival curve for all cause cardiac mortality in disopyramide-treated and non-disopyramide-treated patients with HOCM [60].’’ On Page 9, incorrect citations of Refs. [32,33] within the caption of Table 1. Caption should read: ‘‘Table 1 Effects of beta-blocker, calcium antagonist, disopyramide, and cibenzoline on LV pressure gradient, LV diastolic dysfunction, LV hypertrophy, and end-stage heart failure, and side effects of each drug [40,41].’’ The authors would like to apologize for any inconvenience this may have caused to the readers of the journal.
DOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.02.022 * Corresponding author at: Division of Cardiology, Uwajima City Hospital, 1-1 Goten-machi, Uwajima, Ehime 798-8510, Japan. Tel.: +81 895 25 1111; fax: +81 895 25 5334. E-mail address: [email protected] (M. Hamada). http://dx.doi.org/10.1016/j.jjcc.2014.07.011 0914-5087/ß 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Journal of Cardiology journal homepage: www.elsevier.com/locate/jjcc
Corrigendum
Corrigendum to ‘‘Advances in medical treatment of hypertrophic cardiomyopathy’’ [J. Cardiol. 64 (2014) 1–10] Mareomi Hamada (MD, FJCC)a,*, Shuntaro Ikeda (MD)a, Yuji Shigematsu (MD, FJCC)b a b
Division of Cardiology, Uwajima City Hospital, 1-1 Goten-machi, Uwajima, Ehime 798-8510, Japan Clinical Nursing, Ehime University Graduate School of Medicine, Shitsukawa, Toon-City, Ehime 791-0295, Japan
The author regrets that some of the reference citations in the original publication of this article were incorrect. On Page 6, there is an incorrect citation of Ref. [59] within the caption of Fig. 5. Caption should read: ‘‘Fig. 5. Kaplan–Meier survival curve for all cause cardiac mortality in disopyramide-treated and non-disopyramide-treated patients with HOCM [60].’’ On Page 9, incorrect citations of Refs. [32,33] within the caption of Table 1. Caption should read: ‘‘Table 1 Effects of beta-blocker, calcium antagonist, disopyramide, and cibenzoline on LV pressure gradient, LV diastolic dysfunction, LV hypertrophy, and end-stage heart failure, and side effects of each drug [40,41].’’ The authors would like to apologize for any inconvenience this may have caused to the readers of the journal.
DOI of original article: http://dx.doi.org/10.1016/j.jjcc.2014.02.022 * Corresponding author at: Division of Cardiology, Uwajima City Hospital, 1-1 Goten-machi, Uwajima, Ehime 798-8510, Japan. Tel.: +81 895 25 1111; fax: +81 895 25 5334. E-mail address: [email protected] (M. Hamada). http://dx.doi.org/10.1016/j.jjcc.2014.07.011 0914-5087/ß 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.